BridgeBio reversed premarket gains and tumbled midday Tuesday after the drugmaker's growth disorder treatment topped Wall Street's expectations in a Phase 2 study.Please watch the video at ...

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data ...

BBIO Price Action: At the time of writing, BridgeBio shares are trading 4.5% lower at $27.65, according to data from Benzinga Pro.

Longer follow-up results from a mid-stage trial indicate the company’s treatment for a genetic cause of dwarfism may be competitive to an approved therapy from BioMarin Pharmaceutical.

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the ...

BridgeBio reported top-line data from the midphase PROPEL 2 trial in March 2023 and followed up with six-month data around one year ago. Tuesday, the biotech unwrapped 12- and 18-month data that add ...

The company’s Phase 2 PROPEL2 study results for infigratinib in achondroplasia have shown a consistent and statistically significant increase in average height velocity at both 12 and 18 months, ...

BridgeBio announced Tuesday that its drug candidate infigratinib showed positive Phase II results in treating children with achondroplasia, the most common form of dwarfism, and may have an edge over ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Today, FDA advisers are convening to discuss Lykos ...

Overview A type of bone growth disorder. Due to genetic mutations, the cartilage does not convert into a bone during fetal ...